



**May 5, 2022**  
**Announcement no. 10**

### **Grant of warrants**

The Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR), in accordance with its current authorization to issue warrants to key employees of BioPorto, today issued 270,000 warrants for the subscription of an equal number of shares.

The warrants are issued in accordance with the company’s remuneration policy and the authorization in section 18 a of the Articles of Association.

Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.28 per share corresponding the closing price today on Nasdaq Copenhagen. The warrants vest over a four-year period. The warrants include conditions on claw-back in case of e.g., erroneous financial information and provisions on accelerated vesting in case of e.g., a takeover bid and/or business combinations.

Detailed terms of the new and existing warrants, including applicable vesting schedules, can be found in the Articles of Association on [www.bioporto.com](http://www.bioporto.com) under Investor Relations> Governance> Company Articles.

The theoretical market value of the newly issued warrants is DKK 149,000. The calculation is based on the Black-Scholes formula using an interest rate of 0.50% and the historical volatility of BioPorto A/S’ shares of 27 months calculated to 75.37%.

### **For further information, please contact:**

Tim Eriksen, Zenith Advisory  
Telephone +45 4529 0000, e-mail: [investor@bioporto.com](mailto:investor@bioporto.com)

### **About BioPorto**

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.

BioPorto is headquartered in Hellerup, Denmark and listed on the Nasdaq Copenhagen stock exchange [CPH:BIOPOR]